Impact of Community-Based Clinical Breast Examinations in Botswana.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
01 2021
Historique:
entrez: 6 1 2021
pubmed: 7 1 2021
medline: 6 8 2021
Statut: ppublish

Résumé

We evaluated a clinical breast examination (CBE) screening program to determine the prevalence of breast abnormalities, number examined per cancer diagnosis, and clinical resources required for these diagnoses in a middle-income African setting. We performed a retrospective review of a CBE screening program (2015-2018) by Journey of Hope Botswana, a Botswana-based nongovernmental organization (NGO). Symptomatic and asymptomatic women were invited to attend. Screening events were held in communities throughout rural and periurban Botswana, with CBEs performed by volunteer nurses. Individuals who screened positive were referred to a private tertiary facility and were followed by the NGO. Data were obtained from NGO records. Of 6,120 screened women (50 men excluded), 452 (7.4%) presented with a symptom and 357 (5.83%) were referred for further evaluation; 257 ultrasounds, 100 fine-needle aspirations (FNAs), 58 mammograms, and 31 biopsies were performed. In total, 6,031 were exonerated from cancer, 78 were lost to follow-up (67 for ≤ 50 years and 11 for > 50 years), and 11 were diagnosed with cancer (five for 41-50 years and six for > 50 years, 10 presented with symptoms). Overall breast cancer prevalence was calculated to be 18/10,000 (95% CI, 8 to 29/10,000). The number of women examined per breast cancer diagnosis was 237 (95% CI, 126 to 1910) for women of age 41-50 years and 196 (95% CI, 109 to 977) for women of age > 50 years. Median time to diagnosis for all women was 17.5 [1 to 32.5] days. CBE-detected tumors were not different than tumors presenting through standard care. In a previously unscreened population, yield from community-based CBE screening was high, particularly among symptomatic women, and required modest diagnostic resources. This strategy has potential to reduce breast cancer mortality.

Identifiants

pubmed: 33405960
doi: 10.1200/GO.20.00231
pmc: PMC8081526
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-26

Subventions

Organisme : NCI NIH HHS
ID : R01 CA236546
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA202637
Pays : United States

Références

Acad Pediatr. 2018 Mar;18(2):188-195
pubmed: 28549746
World J Surg Oncol. 2016 Oct 28;14(1):277
pubmed: 27793162
Lancet Oncol. 2013 Apr;14(4):363-70
pubmed: 23375833
Infect Agent Cancer. 2017 Feb 14;12:13
pubmed: 28228841
Oncologist. 2016 Jun;21(6):731-8
pubmed: 27053501
Int J Cancer. 2006 Jan 1;118(1):149-54
pubmed: 16049976
Rofo. 2016 Jan;188(1):33-7
pubmed: 26485700
Front Oncol. 2018 May 29;8:187
pubmed: 29896450
J Glob Oncol. 2018 Jul;4:1-10
pubmed: 30084698
PLoS One. 2019 Jun 20;14(6):e0217938
pubmed: 31220096
Breast. 2013 Oct;22(5):828-35
pubmed: 23489760
Oncologist. 2016 Jun;21(6):739-44
pubmed: 27091419
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 2015 Jun 15;136(12):2875-9
pubmed: 25408458
Ann Oncol. 2016 May;27(5):926-33
pubmed: 26802157
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241264
J Glob Oncol. 2019 Nov;5:1-13
pubmed: 31774713
J Glob Oncol. 2017 Apr;3(2):105-113
pubmed: 28503660
JAMA Oncol. 2017 Nov 1;3(11):1563-1567
pubmed: 28542677
J Natl Cancer Inst. 2011 Oct 5;103(19):1476-80
pubmed: 21862730
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
J Clin Oncol. 2016 Nov 1;34(31):3749-3757
pubmed: 27573661
Mol Clin Oncol. 2017 Dec;7(6):1125-1129
pubmed: 29285387
Oncologist. 2015 Jul;20(7):773-9
pubmed: 26001390
Cancer. 2020 May 15;126 Suppl 10:2379-2393
pubmed: 32348566
Trop Med Int Health. 2012 Aug;17(8):1031-43
pubmed: 22809238
JCO Glob Oncol. 2020 Feb;6:27-34
pubmed: 32031433
Int J Cancer. 2010 Feb 15;126(4):976-84
pubmed: 19697326
Oncologist. 2016 May;21(5):571-5
pubmed: 27009935
J Glob Oncol. 2015 Dec 23;2(1):4-8
pubmed: 28717676

Auteurs

Michael Dykstra (M)

Beth Israel Deaconess Medical Center, Boston, MA.
Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.

Brighid Malone (B)

Bokamoso Private Hospital, Gaborone, Botswana.
Journey of Hope Botswana, Gaborone, Botswana.

Onica Lekuntwane (O)

Journey of Hope Botswana, Gaborone, Botswana.

Jason Efstathiou (J)

Massachusetts General Hospital, Boston, MA.

Virginia Letsatsi (V)

Botswana Ministry of Health and Wellness, Gaborone, Botswana.

Shekinah Elmore (S)

Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC.

Cesar Castro (C)

Massachusetts General Hospital, Boston, MA.

Neo Tapela (N)

Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
University of Oxford, Oxford, UK.

Scott Dryden-Peterson (S)

Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Brigham and Women's Hospital, Boston, MA.
Harvard School of Public Health, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH